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ABSTRACT 
BACKGROUND: 
Many adjuvants have been tried to enhance the analgesic efficacy of local 
anaesthetics in supraclavicular brachial plexus block. From previous studies, it was 
noted that opioids added to local anaesthetics produce comparable analgesia in 
supraclavicular brachial plexus block. Hence, in my study, I have compared a 
group of patients who received bupivacaine alone with the other group of patients 
who received the combination of bupivacaine and buprenorphine. 
STUDY DESIGN: 
A total of 60 patients belonging to ASA status I and II posted for elective 
orthopaedic upperlimb procedures were enrolled and randomly divided into two 
groups of 30 each. 
Group I received 24 ml of 0.25%  bupivacaine and 1 ml NS 
Group II received 24 ml of 0.25% bupivacaine and 3µg/kg buprenorphine. 
VAS score, onset of motor and sensory blockade were observed at fixed interval 
for 24 hours postoperatively. 
SPSS   16.01  Version  were used for descriptive, analytic and comparative 
statistics. 
RESULT: 
Onset of motor blockade delayed in group II.VAS score were found to be better in 
group II. Time to first rescue analgesia was prolonged in group II. 
CONCLUSION: 
The results showed that buprenorphine enhance and prolong the analgesic effect of 
bupivacaine when used for supraclavicular brachial plexus block in patients 
undergoing orthopaedic surgeries.   
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INTRODUCTION 
Peripheral nerve blocks are useful techniques which provide an ideal 
operating condition and perioperative analgesia. Its advantages lie in the least 
changes with vital functions of the body and maintaining the patients in an 
alert, awake condition. 
Among the various approaches for brachial plexus blocks 
supraclavicular approach is more popular and safer. There are various 
techniques to block brachial plexus at supraclavicular level, but ultrasound 
guided technique is preferably used to facilitate the needle positioning and 
decrease the incidence of complications, as it allows visualization of vessels 
and plexus  along with the needle and local anaesthetic spread. 
Although, peripheral nerve blockade is widely used for many 
orthopaedic, vascular and plastic surgeries of prolonged duration, inadequate 
postoperative pain relief is an important concern. To improve the quality and 
to prolong the duration of peripheral nerve blockade, various adjuvants have 
been tried. Demonstration of opioid receptors in the peripheral neurons 
prompted the use of various opioids with local anaesthetics to prolong the 
postoperative  analgesia. 
The present study is designed to compare the ultrasound guided 
supraclavicular brachial plexus block with respect to efficacy of 
buprenorphine in prolonging the postoperative analgesia when added to 
bupivacaine. 
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AIM OF THE STUDY 
To compare ultrasound guided supraclavicular brachial plexus block 
using bupivacaine alone and combination of  bupivacaine and buprenorphine 
in patients undergoing elective upper limb orthopaedic surgeries with respect 
to, 
1) Postoperative analgesia using visual analogue pain scale. 
2) Postoperative analgesic initiation time. 
3) Intraoperative hemodynamics. 
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APPLIED PHYSIOLOGY(11),(28) 
Peripheral nerves are lengthy axons of cell bodies of neurons that are 
situated centrally. A peripheral nerve consists of both motor and sensory 
fibres and are covered by 3 layers. Each nerve fibre is enclosed in a layer 
called neurilemma or axonal membrane. Nerve fibres are enclosed in the layer 
called endoneurium and these collection of bundles are covered by 
perineurium, outer most layer covering the perineurium is called epineurium. 
Based on  the presence or absence for myelin sheath, it can be myelinated or 
unmyelinated nerve fibre. 
During nerve conduction, the signal is conducted downstream the 
neurons by opening or closing of voltage gated ion channels and causes 
reversal of Resting membrane potential to action potential. The action 
potential formation can be divided into 5 steps. 
The normal resting equilibrium potential is about -70mV and is 
maintained by Na+ K+ ATP ase. 
1) A stimulus causes the neuron to depolarise toward the threshold 
potential (-55mV). 
2) Once the threshold potential s is achieved all the Na+ channels open, 
allowing Na+ to enter the cell and the membrane become depolarised. 
3) At the peak action potential (+30mV), K+ ions leak out of the cell to 
restore the electrical neutrality and the  Na+ channels close. 
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4) Hyperpolarisation occurs as K+ continues to leave the cell and makes 
the membrane refractory to further stimulation. 
5) Restoration of resting membrane potential is achieved by Na+/ K+ 
transporter. 
ACTION OF LOCAL ANAESTHETICS(22) 
Local anaesthetics consist of a lipophilic portion and a hydrophilic 
portion with hydrocarbon chain separating the both. Local anaesthetics 
prevent the transmission of nerve impulses by inhibiting the passages of 
sodium ions through voltage gated Na+ channels in the nerve membrane 
(conduction blockade). 
This is brought about by, 
1) Local anaesthetics block conduction by stabilization of the resting 
membrane potential, therefore the permeability changes cannot occur, 
Na+ and K+ ions movement are blocked thereby preventing the 
depolarization. 
2) Unionised molecule of the local anaesthetic diffuses across the lipid       
layer of the axon. After diffusion, the quartenary amine binds with the 
receptor of Na+ channels when it is in inactivated state and 
depolarization is prevented by inhibiting the conformational change 
and stabilize the membrane in this inactivated resting state. 
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PAIN PATHWAY(11) 
Nociceptors are specialized receptors that generate nerve impulses in 
response to noxious stimulus and brain interprets this as pain. Nociceptors are 
free nerve endings of primary afferent fibres of Aδ and C nerve fibres. They 
are distributed throughout the body and can be stimulated by chemical, 
mechanical and thermal stimuli. During tissue damage, inflammatory 
mediators like bradykinin, prostaglandins, cytokines and hydrogen ions are 
released and stimulate the nociceptors directly. Primary sensitization occurs 
which reduce the activation threshold of nociceptors. 
PRIMARY AFFERENT FIBRES: 
Noxious stimuli are carried by Aδ and C fibres and non noxious stimuli 
are carried by Aβ fibres. 
Aβ – They are highly myelinated with large diameter and low 
activation threshold. They respond to light touch. Apart from this, they will 
recruit inhibitory interneurons and inhibit nociceptive input at the same spinal 
segment. 
Aδ  - They are lightly myelinated with smaller diameter. They conduct 
more slowly than Aβ fibres and carry rapid sharp pain. 
C – They are unmyelinated fibres with smallest diameter and hence 
they have slowest conduction. They  carry slow, burning pain. 
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Primary afferent neurons release excitatory neurotransmitters like 
substance P and glutamate.  
 
 
SECONDARY AFFERENT NEURONS: 
They  are located in dorsal horns of spinal cord. Histologically, dorsal 
horn  is divided into ten layers and are called Rexed  laminae. Nociceptive 
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stimuli from Aδ and C primary afferent neurons transmit the impulses to 
secondary afferent neurons that  are  present in  lamina I, II    and V. 
Secondary neurons can be divided into nociceptive specific neurons 
and wide dynamic range neurons. 
ASCENDING TRACTS IN THE SPINAL CORD: 
There are two main pathways. 
1) SPINOTHALAMIC TRACT: Secondary afferent neurons decussate within 
a few segments from the level of  entry into the spinal cord. Then, they ascend in 
contralateral spinothalamic tract and synapse in nuclei in the thalamus. From 
thalamus third order neurons ascend to terminate in somatosensory cortex also 
projects into periaqueductal grey matter. 
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2. SPINORETICULAR TRACT: 
Secondary   afferent  neurons  decussate and ascend contralaterally 
to reach the brainstem reticular formation before reaching thalamus.  
ENDOGENOUS PAIN MODULATION MECHANISMS: 
ENDOGENOUS EXCITATORY MECHANISM: 
Spinal excitatory mechanisms: 
Spinal sensitization is defined as increased excitability and 
spontaneous discharge from spinal nociceptive neurons to a nociceptive 
stimulus. This depends on the NMDA receptor activation which occurs due to 
sustained release of glutamate.  
Descending excitatory mechanisms: 
It is postulated that during nociceptive activity, there is activation of  
“ON” cells and inhibition of “OFF” cells. This may change the normal 
neuronal response to specific neurotransmitters. 
 ENDOGENOUS INHIBITORY MECHANISMS: 
 Spinal mechanisms: 
Melzack and Wall proposed the “Gate control theory”. It postulates 
that there is selective activation of non-nociceptive afferent Aβ fibres which 
will recruit inhibitory interneurons in the substansia gelatinosa producing a 
localized analgesia and decreased pain perception. 
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Diffuse noxious inhibitory controls: 
Periaqueductal grey matter and NRM are important seratonergic and 
noradrenergic inhibitory pathways. There will recruit encephalinergic 
interneurons in spinal cord to produce analgesia. 
 
Superior control centers: 
Cognitive manipulations like distractions and hypnosis can influence pain 
perception. They will alter both the affective and sensory components of pain 
perception. 
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PAIN RATING SCALE 
Visual analogue scale: 
 
The patient is instructed to point a position on the line between the 
faces to indicate how much pain they are experiencing.  The left end denotes 
‘No pain’ and the right end denotes ‘Worst pain ever’. 
Numerical rating scale (NRS)
 
The  patient  is  instructed  to choose  a  number from  0 to 10  that  best  
describes their  current  pain.  0  denotes  ‘No pain’  and  10  denotes  ‘Worst  possible 
pain’. 
Faces Rating Scale (FRS)
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Adults having difficulty in using the numbers on the visual/numerical 
rating scales can be assisted with the use of this six facial expressions 
suggesting a range of pain intensities. Ask the patient to choose the face that  
describes their pain. The extreme left face denotes ‘No hurt’ and the extreme 
right face denotes ‘Hurts worst’. 
Behavioural rating scale: 
Patients who are unable  to provide a self-report of pain this scale can 
be used: scored 0–10 clinical observation 
Face 0 
Facial muscles 
relaxed 
1 
Facial 
muscle 
tension, 
grimace 
2 
constant 
grimace, 
clenched jaw 
Face score: 
Restlessness 
 
 
 
0 
Quiet, relaxed 
appearance, 
normal 
movement 
1 
Occasional 
agitated 
movement 
2 
Frequent 
agitated 
movement 
including 
extremities or 
head 
Restlessness 
score: 
Muscle tone* 0 
Normal 
muscle tone 
1 
Increased 
tone, flexion 
of fingers 
and toes 
2 
Rigid  
Muscle tone 
score: 
Vocalisation** 0 
No abnormal 
sounds 
1 
Occasional 
moans, cries 
and grunts 
2 
Frequent or 
continuous 
moans, cries  or 
grunts 
Vocalisation 
score: 
Consolability 0 
Content, 
relaxed 
1 
Can be 
reassured  
2 
Difficult to 
reassure 
Consolability 
score: 
Behavioural pain assessment scale total (0–10) /10 
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The behavioural pain assessment scale is intended for use with non-
verbal patients unable to expresss self-reports of pain. 
Functional activity score: 
This is an activity-related score. Ask   the  patient to do an activity 
associated to their painful area like cough or movement. 
A – No limitation 
B – Mild limitation 
C - Severe limitation  
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OPIOID RECEPTORS(8),(9),(13),(23),(25) 
Opioid receptors are expressed widely both in the central as well as 
peripheral nervous system. There are mainly three opioid receptors namely 
mu, kappa and delta opioid receptor. 
STRUCTURE AND FUNCTION: 
Opioid receptors are G-protein coupled receptors and they possess 7 
alpha helical transmembrane domains with intracellular loops and 
extracellular N terminus. The difference between the receptors lie in the N 
and C terminus as well as the extracellular loops. 
When the receptor gets activated, G-protein coupling occurs, causing 
activation of the inward rectifying potassium channels, inhibition of adenylyl 
cyclase and voltage dependant calcium channels. Alteration in potassium and 
calcium conductance leads to decrease in neuronal excitability and inhibition 
of neurotransmitter  release. 
Opioid receptors mediate antinociception by variety of mechanisms. 
These include, 
1) Decreasing the Ca2+ current by inhibiting high voltage activated Ca2+ 
channels seems to be the primary mechanism for the inhibiting effects 
of opioids on primary afferent neurons. 
2) Inhibit Ca2+ dependent substance P release from peripheral sensory 
nerve endings. 
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3) Activation of inward rectifying K+ channels causes decrease in 
neuronal excitability. 
Peripheral opioid receptor expression: 
In addition to spinal and centrally placed opioid receptors, they are 
also expressed in peripheral neurons which contributes to antinociception. 
In the peripheral neurons, opioids produce their effect by local 
activation of adenosine tri phosphate(ATP) sensitive potassium channels and 
inhibition of L-type calcium channels. 
Opioid receptors are produced in dorsal root ganglia (DRG) and 
transported by axonal transport to both central and peripheral tissues. It is 
postulated that, during inflammation there is significant increase in opioid 
receptors  both in dorsal root ganglion  and peripheral nerves. The mechanism 
behind these increase in receptors is increase in IL-6 in inflamed tissues 
which induces opioid receptor transcription and translation. Also the 
proinflammatory cytokine Tumour necrosis factor induces opioid receptor 
gene transcription. 
There is increased opioid receptor expression due to alteration in 
subcellular distribution of receptor and disruption of perineural barrier 
thereby providing opioids, a better access to the receptors. Therefore, 
administration of peripheral opioid peptides provide antinociception and  
limits the systemic side effects.    
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APPLIED ANATOMY(12) 
BRACHIAL PLEXUS: 
The effective use of brachial plexus blockade for upper limb surgeries 
needs thorough knowledge about the anatomy of the brachial plexus. It is 
essential to know about the formation, distribution, its vascular, muscular and 
fascial relationships to master this technique. The fibres that constitute the 
plexus are composed of roots, trunks, cords, divisions and terminal nerves. 
FORMATION OF THE PLEXUS 
ROOTS 
The plexus is formed by the anterior primary rami of 5th to 8th cervical 
nerves and 1st thoracic nerve. Occasionally 4th cervical nerve is combined 
with the plexus and called as prefixed plexus (C4-C8) or second thoracic 
nerve is combined with plexus and called as postfixed plexus (C6-T2). 
TRUNKS 
The roots emerge from the intervertebral foramina and lie between the 
anterior and posterior tubercles of the respective transverse process. As the 
roots descend between the scalenus anterior and medius, C5 and C6 roots 
unite to form the upper trunk. C7 root continues as the middle trunk and C8 
and T1 unit to form the lower trunk. Each trunk divides into anterior and 
posterior divisions behind the clavicle and form cords in the axilla. 
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CORDS 
The stream of six divisions join up into three cords; lateral, medial and 
posterior and are composed of as follows. Anterior divisions of upper and 
middle trunks unite to form the lateral cords. Anterior  divisions of  the lower 
trunk continues as the medial cord posterior divisions of upper, middle and 
lower trunks unite to form the posterior cord. 
To summarise the formation of brachial plexus, 
1) Five roots- Ventral primary rami of C5-C8 and T1. 
2) Three trunks 
a. Upper trunk C5-C6 
b. Middle trunk C7 
c. Lower trunk C8-T1 
3) Six divisions – each trunk divides into anterior and posterior divisions. 
4) Three cords 
a. Lateral cord- the fused anterior divisions of upper and middle trunk 
C5-C7. 
b. Medial cord- anterior division of the lower trunk C8-T1. 
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c. Posterior cord- formed by union of posterior divisions of all three 
trunks (C5-T1).  
RELATIONSHIP OF THE BRACHIAL PLEXUS : 
ROOTS 
Lie between the scalenus anterior and medius muscle and above the 2nd 
part of subclavian artery. 
TRUNKS 
Upper and middle trunks lie above the subclavian artery but lower 
trunk behind it as they cross the first rib. 
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DIVISIONS 
At the lateral border of the first rib the trunks give rise to divisions 
behind the clavicle. 
CORDS 
Formed at the apex of the axilla and grouped around the axillary artery. 
 
 
  
19 
 
SYMPATHETIC SUPPLY 
5th and 6 th cervical nerves each receive a grey ramus from the middle 
cervical sympathetic ganglias. 7th and 8th cervical nerves receive from the 
inferior cervical ganglion. 
BLOOD SUPPLY 
The cord and rootlets are supplied by the anterior and posterior spinal 
branches of the vertebral artery. Trunks are supplied directly and indirectly by 
muscular branches of the ascending deep cervical and superior intercostal 
arteries. 
Cords also receive small branches from subclavian, axillary and 
subscapular vessels. 
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BRANCHES 
Branches are given off from roots, trunks and cords. 
BRANCHES FROM ROOTS 
1) Nerve to the serratus anterior C5, C6 and C7. 
2) Muscular branches to 
a. Longus cervices C5-C6 
b. Three scalene muscles C5-C8 
c. Rhomboids C5 
3. Twig to the phrenic nerve C5 
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BRANCHES FROM THE TRUNKS 
1) Suprascapular nerve C5-C6 (Upper trunk) 
2) Nerve to subclavius C5-C6 
BRANCHES FROM THE CORDS 
Lateral Cord 
 Lateral pectoral nerve C5-C7 
 Lateral branch of median nerve C5-C7  
 Musculocutaneous nerve C5-C7 
Medial Cord 
 Medial pectoral nerve C8-T1 
 Medial branch of median nerve C8-T1 
 Medial cutaneous nerve of arm C8-T1 
 Medical cutaneous nerve of forearm C8-T1 
 Ulnar nerve (C7, C8, T1) 
Posterior Cord 
 Upper subscapular nerve (C5-C6) 
 Lower subscapular nerve (C5-C6) 
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 Nerve to lattismus dorsi C6, C7, C8 
 Axillary nerve C5-C6 
 Radial nerve C5-T1 
 
SONOANATOMY OF BRACHIAL PLEXUS(10) 
The landmark to be identified above the first rib is subclavian artery 
which is seen as a prominent pulsatile hypoechoic structure which resembles 
like tennis ball. 
First rib appear as a bright hyperechoic structure with a bony acoustic 
shadow.Brachial plexus appears as multiple hyperechoic ovals or circles 
superior or superolateral to the subclavian artery. The appearance is often 
described as “honey comb pattern” or “bunch of grapes”. 
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The pleura is seen at the same level as rib as hyperechoic line and 
differentiated by the absence of drop out acoustic shadow. 
The smaller artery pulsations are masked by the stronger subclavian 
artery pulsation. This poses threat of injury to these vascular structures, 
hematoma formation and intravascular injection. This can be prevented by 
using colour flow Doppler during the block. 
      
 
 
24 
 
TECHNIQUES OF BRACHIAL PLEXUS 
BLOCK(5),(14),(20) 
Brachial plexus can be blocked at various sites by various approaches 
as follow 
1) Interscalene approach 
2) Supraclavicular approach 
3) Axillary approach 
4) Infraclavicular approach 
SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK 
CLASSIC KULENKAMPFF APPROACH 
In this, the needle insertion point is marked at 1cm superior to the 
clavicular mid point. The needle is inserted parallel to the patient’s head and 
neck. Once the needle contacts the rib at a depth of 3 to 4cm, the needle is 
walked over the rib for paraesthesia. Local anaesthetic solution is given after 
eliciting parasthesia after careful negative aspiration. 
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PLUMB BOB TECHNIQUE 
The needle insertion point is marked superior to the clavicle where the 
sternocleidomastoid muscle gets inserted into the clavicle. The needle is 
inserted at 900 angle to the table. The local anaesthetic solution is given after 
eliciting paraesthesia. 
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SUBCLAVIAN PERIVASCULAR TECHNIQUE 
The intercalene groove is palpated and trace it below to the most 
inferior part which is just posterior to the subclavial artery  pulsation. The 
needle is entered just above and posterior to the arterial pulse and directed 
caudally at a flat angle with the skin. Once the paraesthesia is elicited, local 
anaesthetic is given. 
COMPLICATIONS 
1) Pneumothorax 
2) Horner’s Syndrome 
3) Phrenic nerve blockade 
4) Hemothorax 
5) Hematoma Formation 
ULTRASOUND GUIDED TECHNIQUE(10),(17),(19) 
Here, high frequency ultrasound transducer is used to visualise the 
superficial structures. 
Ultrasound probe is placed in the supraclavicular fossa in a coronal 
oblique plane. The supraclavicular artery pulsation is noted above the 
hyperechoic first rib. The probe is then angled slightly until the 1st rib and 
pleura are simultaneously seen. The hypoecheic nerve  structures are 
visualized superolateral to the artery. Then using “Inplane” technique, the 
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needle is inserted in a lateral to medial direction and guide the needle towards 
the “corner pocket” formed by 1st rib inferiorly, subclavian artery medially 
and the brachial plexus superiorly. Here, lies the lower trunk of plexus and 
failure to block this area results in inadequate ulnar nerve anaesthesia. 
Local anaesthetic spread during injection is observed and the needle 
can be repositioned to ensure drug distribution all around the nerve trunks 
within the plexus. 
Throughout the procedure, the needle tip should be visualized. If the 
tip is not visible, hydrodissection technique can be used to locate the tip of 
the needle. 
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Advantages of Ultrasound Guidance (29) 
Ultrasound guidance with real-time needle visualization in relation to 
anatomic structures and target nerves makes regional anesthesia safer and 
more successful.  
With ultrasound guidance, brachial plexus blockade can lead to  
• Decreased block performance and onset time, 
• Increased success rate and  
• Decreased rate of complications.  
These advantages result in increased operating room efficiency, as well 
as increased patient satisfaction. 
                 Preinjection:                                       Postinjection   
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PHARMACOLOGY OF BUPIVACAINE(1),(22),(31) 
Bupivacaine hydrochloride is 1-butyl 21, 61 Pipecoloxylilide 
hydrochloride. It is a synthetic long acting amide local  anaesthetic. 
EKENSTAM first synthesized bupivacaine in 1957 at A.B. Bafors 
Laboratories in Mo Indel, Sweden. 
PHYSIOCHEMICAL PROPERTIES 
Bupivacaine has a butyl group on the piperidine nitrogen atom and is a 
long acting drug with high anaesthetic potency. It is highly protein bound and 
has high lipid solubility. It is 3 to 4 times potent as lignocaine. It crosses both 
placenta and blood brain barrier. 
1) Molecular weight – 288.42 g/mol 
2) pKa – 8.1 
3) Partition Coefficient- 346 
4) Mean uptake ratio - 3.3 
5) Protein binding- 95 % 
PHARMACOLOGICAL PROPERTIES 
1) Onset- slow  
2) Duration-  Long acting (4- 8 hours) 
 
30 
 
MECHANISM OF ACTION 
Bupivacaine produces electrical stabilization of the membrane by 
action on sodium conductance. 
Inhibiting the conformational change in the membrane by binding with 
inactivated state of Na+ Channel, thereby preventing the  depolarization. 
PHARMACOLOGICAL EFFECTS 
Local  : Nerve blockade 
Regional : Pain, temperature, touch, motor , power and 
vasomotor tone in the region supplied by nerves that 
are blocked. 
Systemic : Effects occurring as a result of systemic absorption 
or IV administration 
On the cardiovascular system, the effect of bupivacaine is dose related. 
At higher concentration, it blocks sufficient cardiac Na+ channels causing 
conduction blockade, decreased myocardial contractility and depressed Vmax 
(maximum depolarization rate of action potential) leading to slower 
conductance. This is manifested as prolonged PR interval and QRS interval on 
ECG. This results in reentrant phenomenon and ventricular arrhythmias. 
Bupivacaine block cardiac Na+ channels during systole. Whereas 
during diastole it  dissociates off these channels at much slower rate than 
lignocaine because of high lipid solubility causing persistent Vmax 
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depression and subsequent cardiac toxicity. This causes difficulty in 
resuscitation when cardiotoxicity occurs. 
PHARMACOKINETICS 
Volume of distribution : 73 Litres 
Terminal Elimination half life : 210 Minutes 
Clearance : 0.58L/ Min 
Plasma Protein binding : 98% 
Metabolism : Liver by Dealkylation to 
pipecolyloxilidine. 
Excretion : 5% by the kidney as unchanged drug and 
the rest as metabolites 
PREPARATION AVAILABLE: 
0.125% 
0.25% 
0.5% 
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PHARMACOLOGY OF BUPRENORPHINE(2),(23),(24) 
Buprenorphine is a semi synthetic highly lipophilic agonist antagonist 
opioid derived from the opium alkaloid thebaine. It is 33 times more potent 
than morphine. 
MECHANISM OF ACTION 
It is a partial agonist at  receptor. Its affinity to  receptor is 55 times 
greater than that of morphine. It also binds to delta and kappa receptors and 
acts as antagonist. Buprenorphine binds with high affinity and also blocks 
voltage gated Na channels and this leads to local anaesthetic property of 
buprenorphine. 
PHARMACOKINETICS 
Buprenorphine undergoes extensive first pass metabolism and has low 
oral bioavailability. But its bioavailability is extensive in sublingual route. 
Administered sublingually drug produces satisfactory analgesia. The time to 
achieve maximum plasma concentration is 40 minutes to 3.5 hours when 
given sublingually or orally whereas 5 minutes after IM injection. 
Its peak effect may take upto 3 hours and duration upto 10 hours. The 
drug remains in the tissues for several days. Elimination  half life is 24 - 60 
hours. 
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Since it is highly lipophilic, its association and dissociation from the 
receptor is very slow. Half life for dissociation is 166 minutes. Compared to 7 
minutes for fentanyl. So plasma levels may not parallel clinical effects. 
Protein binding- 96% 
Volume of distribution -2.8L 
Plasma clearance - 20ml / Kg 
Metabolism: Liver by dealkylation and conjugation to 
norbuprenorphine and buprenorphine- 3 glucuronide through CYP3A4. One of 
the major active metabolites is norbuprenorphine which is a full agonist at mu 
receptor and a partial agonist at kappa receptor. But it has 1/50 th of 
antinociceptive potency and 10 times that of respiratory depressive potency 
when compared to buprenorphine. Buprenorphine 3 glucuronide  and 
norbuprenorphine 3 glucuronide are also  biologically active. Buprenorphine 
3 glucuronide has affinity for the mu recceptor and delta receptor but no 
affinity for kappa receptor. Norbuprenorphine 3 glucuronide has no affinity 
for mu and delta receptor but bind to kappa opioid receptor and produces 
sedative effect but do not depress the respiration. 
Excretion- Most are excreted in bile through feces and 10-35% in 
urine. 
Therefore, Pharmacokinetics are not much altered in patients with 
renal impairement. 
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INTERACTIONS: 
1) CYP3A4 inhibitors – buprenorphine actions will get potentiated when  
used along with the drugs like azole antifungal agents, macrolides, 
ART drugs. 
2) CYP3A4 inducers – buprenorphine actions will be decreased by the 
drugs like phenobarbitonr, phenytoin, benzodiazepines, carbamazepine, 
opioid analgesics, general anaethetic drugs, phenothiazones, sedative 
hypnotics, alcohol and other CNS depressant drugs. 
CONTRAINDICATIONS: 
1. Allergic to the drug 
2. Severe respiratory insufficiency 
3. Severe hepatic impairment 
4. Acute alcoholism or delirium tremens 
PHARMACOLOGICAL ACTIONS: 
CARDIOVASCULAR SYSTEM: 
Buprenorphine produces vasodilatation and a decrease in heart rate and  
blood pressure. Postural hypotension is prominent. Pulmonary edema has 
been reported. 
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CENTRAL NERVOUS  SYSTEM: 
It produces significant respiratory depression with a ceiling effect after 
doses of 0.15 to 1.2mg. Increased doses do not produce further depression and 
may actually result in increased ventilation due to antagonistic action. 
Because of the high affinity and slow dissociation from the receptor its 
reversal is limited. High doses of naloxone are required for reversal of 
respiratory depression. In the epidural space, the high lipid solubility limits 
the cephaled spread of the drug and likelihood of delayed respiratory 
depression than morphine. 
Sedation, drowsiness, miosis, nausea and vomiting are similar to 
morphine. Dysphoria is unlikely. constipation is less prominent than 
morphine. 
ADVERSE EFFECTS: 
CNS: 
 Headache 
 Migraine 
 Drowsiness 
 Somnolence 
 Miosis 
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RESPIRATORY SYSTEM: 
 Respiratory depression 
 Cough 
GASTROINTESTNAL SYSTEM: 
 Constipation 
 Nausea 
 Vomiting 
 Abdominal pain 
 Loose stools 
 Dyspepsia 
SKIN: 
 Pruritis  
 Rash 
    MUSCULOSKELETAL SYSTEM: 
 Arthralgia 
 Myalgia 
 Muscle spasm 
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    PSYCHIATRY: 
 Anxiety 
 Depression 
 Insomnia nervousness 
TOLERANCE AND DEPENDANCE 
There is lower degree of tolerance to buprenorphine. Physical and 
psychological dependence occur with this drug compared to morphine on 
chronic use. 
USE IN OBSTETRICS 
Not recommended during labour because of respiratory depression 
occurs in the neonate and cannot be reversed with naloxone. 
USE IN PEDIATRICS:  
Safety not evaluated 
DOSAGE IN ADULTS: 
Sublingual – 0.4-0.8mg 
IV/IM: 0.3mg 
Intrathecal, epidural and Peripheral nerve blockade- 2 to 4 g/Kg 
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USES: 
1) As an analgesic for long lasting painful conditions like cancer pain. 
2) For control of postoperative pain. 
3) As an analgesic component of balanced anaesthesia (4.5-12g/Kg) 
4) For intraoperative and postoperative analgesia by intrathecal, epidural 
and also through peripheral nerve blocks. 
5) As a maintenance drug for opioid depression patients as an alternative 
to methadone. 
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REVIEW OF LITERATURE 
Regional anaesthetic technique are widely used for orthopaedic 
procedures because of excellent intraoperative and post operative analgesia. 
But, local anaesthetics above cannot provide post operative analgesia for a 
longer duration. 
To overcome this, several adjuvants have been studied along with local 
anaesthetics to prolong the duration of post operative analgesia without much 
side effects. 
 Opioids as adjuvants have been studied for prolongation of 
postoperative analgesia. The mechanism of action postulated was 
1) There would be movement of opioids to their receptors through an 
axoplasmic flow. 
2) Other would be that of a diffusion and subsequent binding to the 
receptors of lamina V in the spinal cord. 
But, Now it has been demonstrated that, peripheral afferent sensory 
fibres contain opioids receptors, in addition to that endogenous opioids also 
been demonstrated in the peripheral sensory fibres. 
SUPRACLAVICULAR APPROACH FOR BRACHIAL PLEXUS BLOCK 
1. Winnie and Ramamoorthy (1977) postulated that the trunks of 
brachial plexus are arranged into 2 groups, the peripheral mantle and central 
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core fibres. The mantle bundle contains the outer motor and inner sensory 
fibres. The core bundle contains outer motor supplying the muscles of 
forearm and inner sensory fibres carrying sensations from the hand. 
Thus, the order of blockade is as follows loss of motor power of 
shoulder and upper arm, loss of sensation in upper arm, loss of motor power 
of the forearm and loss of sensation of the hand.(30) 
2. Brown DL et al (1993) did a study on various sites of brachial plexus 
block. They studied the supraclavicular, interscalene, infraclavicular and 
axillary approaches. They conducted that the supraclavicular block produces 
anaesthesia of the entire upper extremity in an efficient manner than any other 
technique. This is due to arrangement of plexus in a very compact manner in 
this site.(5)  
ULTRASOUND GUIDED TECHNIQUE FOR BRACHIAL 
PLEXUS  BLOCK 
1. Vienna et al (1994) developed the ultrasound guided technique for the 
supraclavicular approach and demonstrated the high success rate with 
this technique  
2.  William et al (2003) compared the ultrasound guided supraclavicular 
brachial plexus block with nerve stimulation technique and found that 
ultrasound guided was superior than nerve stimulator technique.(29) 
3.  Yuan Jia Min et al (2012) studied the complications of ultrasound guided 
and peripheral nerve stimulator guidance brachial plexus block and he 
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found out that ultrasound guided technique decreases the risks of 
vascular puncture and improves the success rate of brachial plexus 
compared with peripheral nerve stimulator technique 
 4.  Krutika  et  al (2013) studied the usefulness of ultrasound guided 
supraclavicular brachial plexus block and compared it with nerve 
stimulator guided technique. Group I – USG guided technique were used 
and Group –II nerve stimulator technique were used. They compared 
block execution time, time of onset of sensory and motor blockade, 
quality of blockade and success rates. From this study they concluded 
that USG guided technique is quick to perform with improved safety in 
positioning the needle and accuracy in visualizing the anatomical 
structures.(16) 
PERIPHERAL ANTINOCICEPTIVE ACTIONS OF OPIOIDS 
1. Hassan et al (1993) have showed that the axonal transport of opioids 
receptors in sciatic nerves is increased in peripheral inflammation with 
increase in number of opioids receptors on peripheral nerve fibres.(13) 
2. Stein et al (1997) demonstrated that peripheral opioid receptors are present 
on peripheral sensory nerve terminals and characteristics are similar to 
those in the brain. Antinociceptive effects of opioids is due to the 
inhibition of calcium dependent release of substance P from spinal 
cord.(25) 
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3. Karakaya  et al (2001) did a study comparing the analgesic efficacy of 
fentanyl when added with bupivacaine for axillary brachial plexus block. 
They concluded that addition of fentanyl almost doubles the duration of 
analgesia when compared with bupivacaine alone.(15) 
4.  Jena et al (2013) did a study to evaluate the effect of butorphanol versus 
placebo as adjuvant to bupivacaine for supraclavicular brachial plexus 
blockade on the onset of blockade and duration of analgesia. They 
calculated that butorphanol prolongs the duration of blockade and 
increase the postoperative analgesia without much adverse effects. 
BUPRENORPHINE WITH LOCAL ANAESTHETICS IN 
BRACHIAL PLEXUS BLOCK 
1. Viel EJ et al (1997), studied the efficacy  of buprenorphine  and     
morphine  in    supraclavicular brachial plexus block. They noted that 
there is significant difference  in duration of analgesia with 
buprenorphine group had two fold greater analgesia  than the morphine 
group.(27) 
2. Kenneth D. Candido et al (2002), conducted a study to evaluate the 
efficacy of buprenorphine in prolonging the analgesia when added to 
local anaesthetic in subclavian perivascular technique. They have 
concluded that there is three fold increased duration of  analgesia in 
buprenorphine group patients when compared to patients given local 
anaesthetic alone.(6) 
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3. Winnie et al (2002), conducted a study comparing buprenorphine added 
to local anaesthetic for axillary brachial plexus block versus local 
anaesthetic alone with regards to postoperative analgesia. 
 Group I received local anaesthetic with buprenorphine in axillary block  
and intramuscular saline, Group II received local anaesthetic alone in 
axillary block and intramuscular buprenorphine and Group III received 
local anaesthetic alone in axillary block and intramuscular saline. 
 Duration of analgesia was compared and concluded that postoperative 
analgesia in Group I was 3 times prolonged than Group III and 2 times 
prolonged than Group II and supported the peripheral action of 
opioids.(30) 
4. Dhrubajyothi Sarkar et al (2010), evaluated the effects of adding 
fentanyl and buprenorphine to local anaesthetics in brachial plexus block 
by comparing 3 groups using subclavian perivascular technique. Group-I 
received the block with local anaesthetic alone. Group-II received the 
block with local anaesthetic and 0.3mg buprenorphine. Group-III 
received the block with local anaesthetic and 50g fentanyl. They 
conducted that the addition of buprenorphine to local anaesthetics 
provides a significant prolongation of analgesia than local anaesthetics 
alone and local anaesthetics with fentanyl with no significant adverse 
effects. 
5. Singam et al (2012), did a study in which Group-C received local 
anaesthetic alone and Group-B received local anaesthetic and 
44 
 
buprenorphine 0.3mg. They concluded that buprenorphine, as adjuvant to 
bupivacaine in brachial plexus block prolonged the duration of analgesia 
without increasing the risk of adverse effects and is excellent choice for 
providing postoperative analgesia.(2) 
6. Bharat et al (2013), conducted a  prospective randomized double blinded 
study and compared the effects of  buprenorphine and clonidine  as 
adjuvants to local anaesthetic 0.25% bupivacaine for supraclavicular 
brachial plexus block. 
 Group B received 0.5% bupivacaine 20 ml + 20 ml NS                           
Group BB received 0.5% bupivacaine 20 ml +0.3mg buprenorphine +19 
mlNS                                                                                                                     
Group BC received 0.5% bupivacaine 20 ml +  150µg clonidine + 19 
mlNS 
 They conclude that Vas score were lower in group with buprenorphine than 
without it at all times except at 24 hour at  which the  three groups  showed  no 
difference between them. Also the time for first rescue analgesic was 
significantly prolonged in buprenorphine (18±6.391)and clonidine group 
(15.3±4.78)  than plain bupivacaine group (9±2.791) .(4) 
7. Ritesh et al (2013), conducted a study on effect of buprenorphine in 
supraclavicular brachial plexus block  on postoperative analgesia. Group 
I  received 0.25% bupivacaine 40 ml and Group II received 0.25% 
bupivacaine and 3 microgram/kg buprenorphine. Onset of action, 
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duration of analgesia, time of first rescue analgesia and number of 
analgesic drug required in the first 24 hours were studied. 
 They concluded that use of buprenorphine in brachial plexus block 
prolongs postoperative analgesia by more than 2 fold.(21) 
8.  Deepali et al (2015), conducted a prospective randomized double blinded 
placebo controlled study and compare the effect of  buprenorphine with 
local anaesthetic in axillary brachial plexus block versus intramuscular 
buprenorphine. 
 Group RB received buprenorphine 2 microgram/kg with local anaesthetic 
in axillary block and 1ml NS intramuscularly. Group SB received 1ml 
NS with local anaesthetic in axillary block and buprenorphine 2 
microgram/kg intramuscularly. 
 They concluded that patients who have received  buprenorphine  in 
axillary block  had significantly prolonged analgesia when compared to 
the patients who have received intramuscular buprenorphine. 
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MATERIALS AND METHODS 
This study was carried out in the orthopaedic theatre, Government 
General Hospital, Chennai after obtaining Institutional approval between Jan 
2015 to June 2015. The aim of the study was to evaluate the efficacy of 
Buprenorphine as an adjuvant to bupivacaine for ultrasound guided 
supraclavicular brachial plexus block in patients undergoing elective upper 
limb surgeries. 
STUDY DESIGN 
The study was a prospective randomized control study. 
SELECTION OF CASES 
60 adult patients in the age group of 20-60 years belonging to ASA I 
and II scheduled to undergo elective upperlimb orthopaedic procedures were 
chosen. All the patients were assessed and those with normal clinical, 
hematological, biochemical and radiological parameters were selected. 
Informed written consent was obtained from all the patients. All the 
patients were randomnly assigned to two groups Group-A and Group-B each 
containing 30 patients. 
Group-A: Patients undergoing supraclavicular brachial plexus block by 
ultrasound guided technique with 25ml of 0.25% Bupivacaine. 
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Group-B: Patients undergoing supraclavicular brachial plexus block by 
ultrasound guided technique with 25ml of 0.25% Bupivacaine and 3g/Kg of 
Buprenorphine. 
INCLUSION CRITERIA 
 Assessed patients of ASA I and II status. 
 Both gender. 
 Normal biochemical and hematological parameters. 
 Age group between 20 -60years 
 Patients weighing 50-70 Kgs. 
 Mallampati score of I and II 
 No known neurological deficit  
 No local sepsis 
 Those who have given valid informed consent 
EXCLUSION CRITERIA 
 Patients who have not given consent. 
 Patients with anticipated difficult airway. 
 Neurological disorders 
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 History of allergy to local anaesthetics 
 History of cardiovascular and respiratory disorders 
 Local bony deformities 
 History of bleeding disorders 
 Extremely obese patients 
MATERIALS REQUIRED 
 Equipments for the block 
 Ultrasound machine 
 Sterile tray for regional blocks  
 Drugs for the block- 0.25% Bupivacaine, Buprenorphine 
 Equipment and drugs for resuscitation 
 Equipments and drugs for conversion to general anaesthesia in case of 
block failure 
METHODS 
PREOPERATIVE PREPARATION 
Patients were assessed preoperatively and the procedure was explained 
to the patients. Written informed consent was obtained. 
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Assessment of pain using VRS- Verbal Rating Scale intraoperatively 
and VAS- Visual analogue score post operatively was explained to the 
patients preoperatively. 
PREMEDICATION 
Patients were not given any premedication. 
CONDUCT OF ANAESTHESIA 
On arrival of the patient in the operating room, monitors were 
connected. Monitors include pulse oximetry, NIBP and ECG and baseline 
vitals signs were recorded. An intravenous access was obtained in the 
opposite arm. The patients were given ultrasound guided supraclavicular 
brachial plexus block as follows. 
PROCEDURE 
The patient is made to lie supine with a small pillow below head and 
neck and turned the head to the side opposite to that to be blocked. 
         The USG probe is cleaned and covered in a sterile cover and the 
patients’ skin is prepared with povidone iodine and drapped with sterile 
towel. The probe is placed and adjusted to visualize the brachial plexus and 
local anaesthetic solution is injected onto the skin at the needle entry point. 
A 100mm long needle is inserted 1 to 2cm away from the central 
border of the probe. The needle angle is maintained at 0-45˚. 
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“Inplane” approach is used for the block. Needle is inserted initially in 
the superficial plane until the needle is visualized on the scan. Once the 
hyperechoic line is seen, it is inserted towards the brachial plexus and placed 
in the cornerpocket. Throughout the procedure the needle tip was traced. 
After careful negative aspiration, local anaesthetic 1-2ml was injected to see 
the spread thereby confirming the needle tip position. Then, by adjusting the 
needle position, drug is deposited all around the brachial plexus. 
EVALUATION OF THE BLOCK 
The following observations were made 
1) Vital signs monitoring: Non- invasive blood pressure and heart rate 
was measured every 1 minute for the first 10 minutes and every 5 
minutes thereafter throughout the intra operative period. ECG and 
SPO2, respiratory rate were monitored continuously. For statistical 
purposes, they were documented at 1, 5, 10, 15, 30 minutes and every 
30 minutes till 2 hours and every 2 hours thereafter. 
2) Immediately following the administration of the drug, patients were 
evaluated every minute till the onset of sensory and motor blockade. 
3) Time of onset of sensory blockade was tested by assessment of 
pinprick sensation with a 26G hollow needle. 
4) Onset of motor blockade was assessed by loss of shoulder abduction. 
Failure of the block to appear in 20 minutes was taken as failure and 
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the patients were administered general anaesthesia and were excluded 
from the study.  
5) After confirmation that the block has taken up, surgery was started. 
During the surgical procedure, the degree of pain was assessed with a 3 
point verbal rating score (VRS). 
0- No Pain 
1-  Pain 
2-  Unbearable Pain 
If VRS >1, patients were administered general anaesthesia and were 
excluded from the study. 
6) Local anaesthetic toxicity manifestations like circumoral numbness, 
tinnitus, twitching, convulsions etc, were looked for and appropriate 
measures were planned. 
7) Complications like intravascular injection and pneumothorax were 
looked for and appropriate measures were planned. 
8) Duration of analgesia were tested postoperatively using VAS score 
every ½ Hour for the first 6 hours thereafter every 1 hour till  12 hours, 
thereafter every 4 hours till 24 hours. 
Patients were given rescue analgesia with intramuscular diclofenac 75 
mg when VAS > 4. 
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9) Side Effects of opioids are to be looked for 48 Hours. 
a. Nausea and vomiting 
b. Pruritis 
c. Urinary Retention 
d. Hypotention 
e. Headache 
f. Respiratory Depression defined as RR <10/ minute 
g. Any other neurological depression 
PARAMETERS STUDIED 
Onset of Sensory Analgesia 
This is the time in minutes from the injection of the drug to the lack of 
appreciation of pinprick sensation. 
Onset of motor blockade 
This is the time in minutes from the time of drug injection to the loss 
of shoulder abduction. 
Duration of Analgesia 
This is the time in hours from the onset of analgesia to the time of 
administration of rescue analgesia. 
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Side effects of Buprenorphine 
All the patients included in the study were monitored for a period of 24 
hours from the time of administration the drug. All the parameters were 
subjected to statistical analysis. 
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STATISTICAL ANALYSIS 
The data were analysis using SPSS (Statistical Package for Social Science) 
Version 16.01. The data collected were scored and analyzed, Continuous variables were 
presented as means with Standard deviation (sd) and categorical variables were 
presented as frequency and percentages. Student t-test was used for testing the 
significance of all the variables (Mean & Sd) in both the group. Chi-square test was 
used to compare proportions. All the Statistical results were considered significant at P 
value = 0.05. 
Sample Selection 
Pilot study was done with a sample size of 6 patients in each group, before the start  of 
the study to decide on sample size. The mean and standard deviation of insertion time 
was calculated from pilot study.  The sample size is calculated based on the formula 
given in NTI   Bulletin 2006. (Sample size determination in health studies, 
V.K.Chadha,Sr. Epidemiologist,   National Institute Bulletin 2006, 42/3 & 4m 55-62.). 
From the pilot study the pilot study got the value of mean and standard deviation of 
duration of Analgesia of Group-1 (4.43 ± 0.62) and Group-II (5.05 ± 1.65).  
       [ Z1-α/2 + Z 1-β] 2  ( 22 )   
n =      - -- -- -- -- - -- -- - -- -- -- - -- -- -- - -- -- -- - --                =     (8.98 * 5.09)/ 0.38  
                (d) 
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         n = 23.132/0.384  
         n =60.24 (60) 
Z1  -α/2   = 1.96  (5%) 
Z1 -β     = 1.037 ( 85 % Power) 
          [ Z1-α/2 + Z 1-β] 2  = (1.96 +1.037 )2   = 8.98  
S = (s1 +s2) / 2              
S =(0.62+1.65)/2 =2.27/2 =1.135 
S2 = (1.135)2=1.288 
2 2=1.288*2 =2.57645    2.576 
        d=(Mean1 –Mean2) 
          = (4.43-5.05)= -0.62 
        d 2  = 0.3844    
 
From the above calculation sample size was decided as 60 (30 for each group) 
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OBSERVATIONS AND RESULTS 
The patients included in this study were divided into two groups 
consisting of 30 patients each. 
Group I  (n =30) received 0.25% bupivacaine  
Group II  (n =30) received 0.25% bupivacaine + 3 microgram/kg 
buprenorphine. 
                                         AGE 
Age Group 
GROUP-I GROUP-II 
No of 
Patients( N ) 
Percentage 
( % ) 
No of 
Patients( N ) 
Percentage 
( % ) 
20 – 30 15 50.00 9 30.00 
30 – 40 9 30.00 10 33.30 
40 – 50 3 10.00 5 16.70 
50 – 60 3 10.00 6 20.00 
TOTAL 30 100 30 100 
Mean 33.37 38.17 
Sd 11.17 11.11 
t- value 1.67 
p-value 0.10 
Significance Not  Significant 
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Majority of the Group I patients belonged to 20 -30 years age group 
 (n =15, 50%) with a mean age group of 33.37 years. In Group II patients, 
majority belonged to 30 -4- years age group(n =10, 33.3%) with a  mean age 
group of 38.17 years. The association between the  intervention groups and 
age distribution is considered to be not  statistically significant since p> o.o5 
as per student t-test.                                          
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SEX 
Sex 
GROUP-I GROUP-II 
No of 
Patients(N) 
Percentage 
(%) 
No of 
Patients 
(N) 
Percentage 
(%) 
Male 11 36.67 8 26.67 
Female 19 63.33 22 73.33 
Total 30 100 30 100 
Ratio(Male : 
Female) 11 : 19  8 : 22  
Chi-Square 0.69 
p-value 0.41 
Significance Not  Significant 
Majority of the Group I patients belonged to female gender  
(n= 19,63.33%). In Group II patients also, majority belonged to female gender 
(n =22,73.33%).The association between the intervention groups and gender 
distribution is considered to be not statistically significant since p >0.05 as 
per chi square test. 
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WEIGHT 
 
Majority of the Group I patients belonged to 50 -55 kgs (n =22, 
73.33%) with a mean weight of 57.37 kgs. In Group II patients also, majority 
belonged to 50-55 kgs (n =20,66.67%) with a mean weight of 58.40 kgs. The 
association between intervention groups and weight distribution is considered 
to be not statistically significant since p> 0.05 as per student t- test. 
Weight 
GROUP-I GROUP-II 
No of 
Patients( N ) 
Percentage 
( % ) 
No of 
Patients( N ) 
Percentage 
( % ) 
50 – 55 22 73.33 20 66.67 
56- 60 8 26.67 10 33.33 
 
TOTAL 
30 100 30 100 
Mean 57.37 58.40 
Sd 3.74 3.64 
t- value 1.09 
p-value 0.28 
Significance Not  Significant 
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BODY MASS INDEX 
Group Mean Standard Deviation 
GROUP-I 19.42 0.97 
GROUP-II 19.71 0.89 
t-value  1.23 
p-value 0.22 
Significance Not Significant 
 
In Group I patients the mean body mass index is 19.42 with standard 
deviation of 0.97. In Group II patients, the mean body mass index is 19.71 
with standard deviation of 0.89. The association between the intervention 
groups and body mass index distribution is considered to be not statistically 
significant since p > 0.05 as per student t- test. 
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ASA STATUS 
STATUS 
GROUP-I GROUP-II 
No of 
Patients( N ) 
Percentage 
( % ) 
No of 
Patients( N ) 
Percentage 
( % ) 
I 22 73.33 24 80 
II 8 26.67 6 20 
TOTAL 30 100 30 100 
 
 
Majority of Group I patients belonged to ASA I (n = 22, 73.33%). In 
Group II patients also, majority belonged to ASA I (n = 24, 80%) 
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DIAGNOSIS 
DIAGNOSIS 
GROUP-I GROUP-II 
No of 
Patients 
(N) 
Percentage 
( % ) 
No of 
Patients 
( N) 
Percentage 
( % ) 
Lt Both Bone fore arm 
Fracture 
2 6.67 1 3.33 
Lt Capitulum Fracture 1 3.33 0 0 
Lt distal radius 
Fracture 
2 6.67 2 6.67 
Lt Lateral Condyle 
humerus 
1 3.33 0 0 
Lt Neglected Elbow 
dislocation 
1 3.33 0 0 
Lt Non Union radius 2 6.67 3 10 
Lt olecranon fracture 1 3.33 1 3.33 
Lt proximal Ulna 
Fracture 
1 3.33 1 3.33 
Lt shaft of humerus 
fracture 
3 10.00 4 13.33 
Rt Distal humerus 
fracture 
1 3.33 2 6.67 
Rt Both bone forearm 
fracture 
7 23.33 8 26.68 
Rt distal humerus 
fracture 
1 3.33 1 3.33 
Rt distal radius 
fracture 
3 10.00 4 13.34 
RtGaleazzi fracture 1 3.33 0 0 
Rt olecranon fracture 1 3.33 1 3.33 
Rt proximal ulna 
fracture 
0 0.00 1 3.33 
Rt shaft of  humerus 
fracture 
2 6.67 1 3.33 
TOTAL 30 100 30 100 
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Majority of Group I patients had both bone fracture (n =7, 23.33%). 
 In Group II patients also, majority had  both bone fracture(n =8, 26.68%). 
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10
10.2
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10.8
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11.4
11.6
11.8
GROUP-I GROUP-II
11.67
11.5
ONSET OF SENSORY BLOCKADE (IN  MINUTES)
M
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S
C
O
R
ONSET OF SENSORY BLOCKADE ( IN MINUTES) 
Group Mean Standard Deviation 
GROUP-I 11.67 0.76 
GROUP-II 11.50 0.90 
t-value  0.78 
p-value 0.44 
Significance Not Significant 
 
The mean  time of onset  of sensory blockade in Group I is 11.67 
minutes with standard deviation of 0.76. The mean onset time in Group II is 
11.50 minutes with standard deviation of 0.90. The association between the 
intervention groups and onset of sensory blockade is considered to be not 
statistically significant since p > 0.05 as per student t- test. 
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ONSET OF MOTOR BLOCKADE (IN MINUTES) 
Group Mean Standard Deviation 
GROUP-I 9.27 0.74 
GROUP-II 9.70 0.79 
t-value  2.19 
p-value 0.03 
Significance Significant 
 
The mean time of onset of  motor blockade in Group I patients is 9.27 
minutes with standard deviation of 0.74. The mean time of onset in Group II 
patients is 9.70 minutes with standard deviation of 0.79. The association 
between intervention groups and onset of motor blockade is considered to be 
statistically significant since p <0.05 indicating true difference between 
intervention groups. 
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CLINICAL SIGNIFICANCE: 
The mean time of onset of motor blockade was meaningfully less in 
bupivacaine group compared to  buprenorphine group by 0.43 minutes with a 
p value of 0.03 as per student t- test. This significant difference in decrease in 
onset of motor blockade in bupivacaine group compared to buprenorphine 
group is true and has not occurred by chance.  
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DURATION OF ANALGESIA (IN HOURS) 
Group Mean Standard Deviation 
GROUP-I 5.03 0.24 
GROUP-II 10.08 0.44 
t-value  55.00 
p-value 0.0001 
Significance Significant 
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The mean duration of analgesia in Group I is 5.03 hours with standard 
deviation of 0.24.The mean duration of analgesia in Group II is 10.08 hours 
with standard deviation of 0.44. The association between intervention groups 
and duration of analgesia is considered to be statistically significant since p < 
0.05 as per student t- test indicating true difference among intervention 
groups. 
CLINICAL SIGNIFANCE: 
The mean duration of analgesia was meaningfully increased in 
buprenorphine group as compared to bupivacaine group by 5.05 hours with a 
p value of 0.0001 as per student t- test. This significant difference in increase 
in duration of analgesia in buprenorphine group compared to bupivacaine 
group is true and not occurred by chance and we can safely conclude that 
buprenorphine added to bupivacaine in supraclavicular brachial plexus block 
in patients undergoing elective upper limb surgeries significantly increase the 
duration of analgesia compared to bupivacaine alone. 
 
 
 
 
 
 
69 
 
PULSE RATE 
Time 
GROUP-I GROUP-II t-
value 
p-
value Significance Mean Sd Mean Sd 
Base Line 79.93 12.02 80.60 10.87 0.23 0.82 NS 
5 Minutes 78.97 12.01 80.23 9.87 0.45 0.66 NS 
10 Minutes 78.70 10.76 80.63 9.72 0.73 0.47 NS 
15 Minutes 78.70 10.51 80.30 8.57 0.65 0.52 NS 
30 
Minutes 78.50 11.02 79.87 9.79 0.51 0.61 NS 
60 Minutes 78.50 10.44 79.50 9.44 0.39 0.70 NS 
90 Minutes 78.43 10.69 78.83 9.82 0.15 0.88 NS 
120 Minutes 78.40 10.02 79.73 9.77 0.52 0.60 NS 
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 Most of the bupivacaine group patients had mean pulse rate ranging 
from 78.40 bpm to 79.93 bpm between 0 minutes and 120 minutes. Similarly 
bupreorphine group patients had mean pulse rate ranging from 78.83 bpm to 
80.63 bpm between 0 minutes and 120 minutes. The association between the 
intervention groups and pulae rate is considered to be not statistically 
significant since p >0.05 as per student t- test. 
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                         SYSTOLIC BLOOD PRESSURE 
Time 
GROUP-I GROUP-II t-value p –value Significance Mean Sd Mean Sd 
BaseLine 120.13 6.81 118.80 6.21 0.79 0.43 NS 
5Minutes 119.53 7.91 117.93 7.31 0.81 0.42 NS 
10Minutes 119.40 6.95 117.07 7.25 1.27 0.21 NS 
15Minutes 119.67 6.19 117.87 5.63 1.83 0.07 NS 
30Minutes 119.47 7.03 117.20 5.16 1.42 0.16 NS 
60Minutes 119.33 6.35 117.27 3.98 1.51 0.14 NS 
90Minutes 119.13 4.66 116.93 5.63 1.65 0.10 NS 
120Minutes 119.13 5.50 116.93 4.60 1.68 0.10 NS 
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Most of the bupivacaine group patients had mean systolic blood 
pressure ranging  from 119.13 mmHg to 120.13 mmHg between 0 minutes and 
120 minutes. Similarly in buprenorphine group patients, the mean blood 
pressure ranging from 116.93 mmHg to 118.80 mmHg between 0 minutes and 
120 minutes. The association between the intervention groups and systolic 
blood pressure is considered to be not statistically significant since p >0.05 as 
per student t-test.  
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DIASTOLIC BLOOD PRESSURE 
Time Group-I Group-II t-value 
p-
value Significance Mean Sd Mean Sd 
BaseLine 74.20 4.62 74.67 3.25 0.45 0.65 NS 
5Minutes 73.67 5.10 74.27 3.74 0.52 0.61 NS 
10Minutes 73.73 5.84 74.00 3.32 0.22 0.83 NS 
15 
Minutes 73.33 6.16 73.93 2.95 0.48 0.63 NS 
30 
Minutes 73.07 4.84 73.80 2.43 0.74 0.46 NS 
60 
Minutes 73.07 4.54 73.27 1.34 0.23 0.82 NS 
90 
Minutes 73.13 4.19 73.60 1.43 0.58 0.57 NS 
120 
Minutes 73.20 4.35 73.27 2.00 0.08 0.94 NS 
Most of the bupivacaine group patients had mean diastolic blood 
pressure ranging from 73.07 mmHg to 74.20 mmHg between 0 minutes and 
120 minutes. Similarly in buprenorphine group patients, the mean diastolic 
blood pressure was ranging from 73.27 mmHg to 74.0 mmHg between 0 
minutes and 120 minutes. The association between the intervention groups 
and diastolic blood pressure is considered to be not statistically significant 
since p >0.05 as per student t-test. 
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MEAN ARTERIAL PRESSURE 
Time 
GROUP-I GROUP-II t-value p-value Significance Mean Sd Mean Sd 
BaseLine 89.13 4.90 89.10 3.45 0.03 0.98 NS 
5Minutes 88.63 5.68 88.63 4.04 0.01 1.00 NS 
10Minutes 88.67 5.34 88.33 3.33 0.29 0.77 NS 
15Minutes 88.50 5.23 88.17 2.71 0.31 0.76 NS 
30Minutes 88.20 4.58 88.00 2.48 0.21 0.83 NS 
60Minutes 88.17 4.87 87.57 1.81 0.63 0.53 NS 
90Minutes 88.03 4.05 87.67 2.17 0.44 0.66 NS 
120Minutes 88.13 4.21 87.53 2.08 0.70 0.49 NS 
Most of the bupivacaine group patients had mean arterial pressure 
ranging from 88.03 mmHg to 89.13 mmHg betweeen 0 minutes and 120 
minutes. Similarly the buprenorphine group patients had mean arterial 
pressure ranging from 87.53 mmHg to 89.10 mmHg between 0 minutes and 
120 minutes. The association between the intervention groups and the mean 
arterial pressure is onsidered to be not statistically significant since p >0.05 
as per student t-test. 
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SpO2 
Time GROUP-I GROUP-II t-
value 
p-
value 
Significance 
Mean Sd Mean Sd 
BaseLine 99.00 0.00 99.00 0.00 - - - 
 5Minutes 99.00 0.00 99.00 0.00 - - - 
10Minutes 99.00 0.00 99.00 0.00 - - - 
15Minutes 98.93 0.25 99.00 0.00 1.44 0.16 NS 
30Minutes 98.97 0.18 99.00 0.00 1.00 0.32 NS 
60Minutes 99.00 0.00 99.00 0.00 -         - - 
90Minutes 99.00 0.00 99.00 0.00 - - - 
120Minutes 98.97 0.18 99.00 0.00 1.00 0.32 NS 
  4  Hours 99.00 0.00 99.00 0.00 - - - 
  6  Hours 99.00 0.00 99.00 0.00 - - - 
  8  Hours 99.00 0.00 99.00 0.00 - - - 
10 Hours 99.00 0.00 99.00 0.00 - - - 
12 Hours 98.97 0.18 99.00 0.00 1.00 0.32 NS 
16 Hours 99.00 0.00 99.00 0.00         - - - 
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Most of the bupivacaine group patients had mean spo2 ranging from 98.97% 
to 99% between 0 minutes and 16 hours. Similarly in buprenorphine group 
patients the mean spo2 was 99% between 0 minutes and 16 hours. The 
association between the intervention groups and spo2 is considered to be not 
statistically significant since p >0.05  as per student t- test. 
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RESPIRATORY RATE 
Time 
GROUP-I GROUP-II t-
value 
p-
value Significance Mean Sd Mean Sd 
BaseLine 15.40 0.50 15.40 0.50 0.01 1.00 NS 
5Minutes 15.37 0.49 15.37 0.49 0.01 1.00 NS 
10Minutes 15.37 0.49 15.40 0.50 0.26 0.80 NS 
15Minutes 15.37 0.49 15.37 0.49 0.01 1.00 NS 
30Minutes 15.37 0.49 15.37 0.49 0.26 0.80 NS 
60Minutes 15.37 0.50 15.37 0.50 0.01 1.00 NS 
90Minutes 15.37 0.50 15.37 0.49 0.01 1.00 NS 
120Minutes 15.37 0.49 15.37 0.49 0.01 1.00 NS 
4  Hours 15.37 0.49 15.37 0.49 0.01 1.00 NS 
6  Hours 15.37 0.49 15.40 0.50 0.26 1.00 NS 
8 Hours 15.37 0.49 15.37 0.49 0.01 1.00 NS 
10 Hours 15.37 0.49 15.37 0.49 0.01 1.00 NS 
12 Hours 15.37 0.62 15.37 0.49 0.01 1.00 NS 
16 Hours 15.43 0.57 15.33 0.48 0.74 0.46 NS 
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Most of the bupivacaine group patients had respiratory rate ranging 
from 15.37 breaths/min to 15.43 breaths/min between 0 minutes and 16 hours. 
Similarly in buprenorphine group patients, the respiratory rate ranging from 
15.33 breaths/min to 15.40 breaths/min between 0 minutes and 16 hours. The 
association between the intervention groups and respiratory rate is considered 
not to be statistically significant since p >0.05 as per student t- test. 
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VISUAL ANALOGUE SCALE 
Time 
Group-I Group-II 
Mode Mode 
Scale 2 0 0 
Scale 4 0 0 
Scale 5 2 0 
Scale 6 4 0 
Scale 7 4 0 
Scale 8   4 0 
Scale 10 0 2 
Scale 11 0 3 
Scale 12 0 4 
 
Most of the bupivacaine  group patients had VAS score >4  at 6 hours, 7 
hours and 8 hours postoperatively while in buprenorphine group, most of the 
pateints had VAS > 4 at 12 hours postoperatively. The association between 
intervention groups and VAS is considered to be statistically significant. 
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RAMSAY SEDATION SCALE 
Time 
GROUP-I GROUP-II t-
value 
p-
value Significance Mean Sd Mean Sd 
BaseLine 1.00 0.00 1.00 0.00 - - NS 
15Minutes 1.87 0.35 1.90 0.31 0.40 0.69 NS 
30Minutes 2.00 0.00 2.00 0.00 - - NS 
1 Hour 2.00 0.00 2.00 0.00 - - NS 
2 Hours 2.00 0.00 2.00 0.00 - - NS 
4  Hours 2.03 0.18 2.00 0.00 1.00 0.32 NS 
6  Hours 2.03 0.18 2.00 0.00 1.00 0.32 NS 
8  Hours 1.97 0.18 2.00 0.00 1.00 0.32 NS 
10 Hours 1.23 0.43 2.00 0.00 9.76 0.0001 NS 
12 Hours 1.00 0.00 1.50 0.51 5.39 0.0001 NS 
16 Hours 1.00 0.00 1.00 0.00 - -  
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 Most of the patients in bupivacaine group had ramsay sedation score 
ranging from 1.00 to 2.03 between 0 minutes and 16 hours. Similarly in 
buprenorphine group ramsay sedation score ranging from 1.00 to 2.00 
between 0 minutes and 16 hours. The association between the intervention 
groups and ramsay sedation score is considered to be not statistically 
significant since p >0.05 as per student t-test. 
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RESCUE ANALGESIC REQUIREMENT (HOURS) 
Group Mean Standard Deviation 
GROUP-I 7.10 0.40 
GROUP-II 13.10 0.96 
t-value 31.58 
p-value 0.0001 
Significance Significant 
 
The mean time at which first rescue analgesic given in bupivcaine group is 
7.10 hours while in buprenorphine group, the mean time is 13.10 hours.The 
association between the intervention groups and the first rescue analgesic ime 
is considered to be statistically significant since p value is <0.05 as per 
student t - test. 
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DISCUSSION 
The aim of the study was to compare the  ultrasound guided 
supraclavicular brachial plexus block using bupivacaine alone with 
combination of  bupivacaine and buprenorphine in patients undergoing 
elective upper limb orthopaedic surgeries with respect to, 
1) Postoperative analgesia using visual analogue pain scale. 
    2) Postoperative analgesic initiation time. 
    3) Intraoperative hemodynamics. 
In this study, ultrasound guided supraclavicular brachial plexus block 
is used due to its gained popularity because of less failure rate and less 
complications with this technique. 
Krutika  et  al (2013)  performed ultrasound guided supraclavicular 
brachial plexus block and compared it with nerve stimulator guided 
technique. Group I – USG guided technique was used and Group –II nerve 
stimulator technique was used. They compared block execution time, time of 
onset of sensory and motor blockade, quality of blockade and success rates. 
From this study they concluded that USG guided technique is quick to 
perform with improved safety in positioning the needle and accuracy in 
visualizing the anatomical structures. The success rate in ultrasound group 
was 96.67% compared to 80% in nerve stimulator group.(16) 
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Vienna et al (1994), developed the ultrasound guided technique for the 
supraclavicular approach and demonstrated the high success rate with this 
technique. 
Stein et al (1997) demonstration of presence of  peripheral opioid 
receptors on  sensory nerve terminals prompted the use of opioids in 
peripheral nerve blocks for the prolongation of post operative analgesia.(25) 
In the study of Kenneth D.Candido et al(2002), the mean weight of 
patients was 74.65 kgs and 0.3 mg of buprenorphine was used. In this study, 
the mean weight of the patients was 58.4 kgs and buprenorphine was used on 
a weight basis at 3µg/kg.(6) 
In this study, the parameters compared are onset of sensory and motor 
blockade, duration of analgesia,   intraoperative and post operative heart rate, 
systolic blood pressure, diastolic blood pressure, mean blood pressure, Spo2, 
respiratory rate, Ramsay sedation scale, Visual analogue scale and First 
rescue analgesic time. 
In this study,  
ONSET OF SENSORY BLOCKADE: 
The mean  time of  onset  of sensory blockade in Group I (bupivacaine 
alone) is 11.67 minutes. The mean onset time in Group II (bupivacaine and 
buprenorphine) is 11.50 minutes which is statistically insignificant as pointed 
out in the study by Bharat et al(2013).(4) 
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ONSET OF MOTOR BLOCKADE: 
The mean time of onset of motor blockade in Group I (bupivacaine 
alone) patients is 9.27 minutes. The mean time of onset in Group II 
(bupivacaine and buprenorphine) patients is 9.70 minutes which is 
statistically significant.But in the study conducted by Bharat et al (2013), 
there was no significant difference in the onset time of motor blockade 
between the two groups.(4) 
DURATION OF ANALGESIA: 
The mean duration of analgesia in Group I (bupivacaine alone)  is 5.03 
hours. The mean duration of analgesia in Group II(bupivacaine and  
buprenorphine)   is 10.08 hours which is statistically significant. Thus 
addition of buprenorphine  provides a significant prolongation of analgesia as  
pointed out in the study by Kenneth  D.Candido and colleagues (2002).(6)   In 
their  study, adddition of buprenorphine 0.3 mg conferred analgesia of 22.3 
hours compared to 6.6 hours in local anaesthetic alone. This is also  
consistent with  the study done by Bharat et al(2013).(4)  In this study, it was  
found out that,  there was statistically significant difference in the  duration 
of  analgesia between the two groups. 
PULSE RATE: 
Most of the bupivacaine group patients had mean pulse rate ranging 
from 78.40 bpm to 79.93 bpm whereas buprenorphine group patients had 
mean pulse rate ranging from 78.83 bpm to 80.63 bpm which is statistically 
insignificant as pointed out  in the study by Bharat et al (2013)(4) and 
J.E.Bazin et al (1997).(3) 
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SYSTOLIC BLOOD PRESSURE: 
In bupivacaine group, patients had mean systolic blood pressure 
ranging  from 119.13 mmHg to 120.13 mmHg whereas in buprenorphine 
group patients, the mean blood pressure ranging from 116.93 mmHg to 118.80 
mmHg which is statistically insignificant as found out in the study by 
J.E.Bazin et al (1997).(3) 
DIASTOLIC BLOOD PRESSURE: 
In bupivacaine group, patients had mean diastolic blood pressure 
ranging from 73.07 mmHg to 74.20 mmHg whereas, in buprenorphine group 
patients, the mean diastolic blood pressure was ranging from 73.27 mmHg to 
74.0 mmHg which is statistically insignificant as found out in the study by 
J.E.Bazin et al (1997).(3) 
MEAN ARTERIAL BLOOD PRESSURE: 
Most of the bupivacaine group patients had mean arterial pressure 
ranging from 88.03 mmHg to 89.13 mmHg whereas in buprenorphine group, 
patients had mean arterial pressure ranging from 87.53 mmHg to 89.10 mmHg 
which is statistically insignificant as pointed out by Bharat and his colleagues 
(2013).(4) 
SPO2: 
Most of the bupivacaine group patients had mean spo2 ranging from 
98.97% to 99% whereas in buprenorphine group patients,  the mean spo2 was 
99%  which is statistically insignificant as found out by Bharat et al (2013).(4) 
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RESPIRATORY RATE: 
In bupivacaine group, patients had respiratory rate ranging from 15.37 
breaths/min to 15.43 breaths/min whereas in buprenorphine group patients, 
the respiratory rate ranging from 15.33 breaths/min to 15.40 breaths/min 
which is statistically insignificant as pointed out in the study done by Bharat 
et al (2013).(4) 
VISUAL ANALOGUE SCORE: 
In bupivacaine group, the mode for visual analogue score is 6,7,8 hours 
whereas in buprenorphine group, mode for visual analogue score is 12 hours 
which is statistically significant.After 12 hours there was no difference in 
visual analogue score between the two groups. This result is consistent with 
the study by Bharat et al (2013), where the visual analogue score was lower 
for buprenorphine group than plain bupivacaine group at all times except at 
24 hours at which there was no difference between the two groups.(4) 
RAMSAY SEDATION SCORE: 
In bupivacaine group, most of the patients  had  ramsay sedation score 
ranging from 1.00 to 2.03whereas  in buprenorphine group, ramsay sedation 
score ranging from 1.00 to 2.00 which is statistically insignificant. But, in the 
study by Bharat et al (2013), there was higher sedation score was achieved in 
buprenorphine group compared to bupivacaine group.(4) 
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FIRST RESCUE ANALGESIC TIME: 
The mean time at which first rescue analgesic given in bupivcaine 
group is 7.10 hours with SD 0.4, while in buprenorphine group, the mean time 
is 13.10 hours witg SD 0.96, which is statistically significant. This is 
consistent with the study by Bharat et al (2013), where the mean time of 
initiation of first rescue analgesic is 9 hours with SD 2.7 in bupivacaine  
group, whereas in buprenorphine group, the mean time  was 18 hours with SD 
6.3.(4) 
SIDE EFFECTS: 
None of the patients in the two groups showed side effects like nausea, 
vomiting, hypotension, constipation, sedation or respiratory depression as 
pointed out in the study by Kenneth D. Candido et al ( 2002), where none of 
the patients developed opioid related side effects.(4) 
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SUMMARY 
For ultrasound guided supraclavicular brachial plexus block, one group 
received bupivacaine alone anad other group received bupivacaine and 
buprenorphine. On comparing the two groups, it was found out that, 
Onset of sensory blockade was similar in both the groups. 
Onset of motor blockade was found to be earlier in bupivacaine alone 
group. 
Duration of analgesia was significantly prolonged in group that 
received buprenorphine compared to bupivacaine alone. 
The need for rescue analgesic is significantly delayed in the group that 
received buprenorphine compared to bupivacaine alone. 
There was no significant difference in the hemodynamic parameters in  
both the groups.  
There was no opioid related side effects in both the groups. 
No other complications were seen in both the groups. 
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CONCLUSION 
From this study, it  is inferred that the addition of buprenorphine to 
0.25% bupivacaine definitely  prolonged the duration of analgesia by two fold 
when compared to 0.25% bupivacaine alone. 
To conclude that, addition of 3µ/kg of  buprenorphine to 0.25% 
bupivacaine in ultrasound guided supraclavicular brachial plexus block 
confers a significant advantage over plain bupivacaine in terms of duration of 
analgesia and need for rescue analgesia. 
 
  
BIBLIOGRAPHY 
1. Alfred Goodman and Gillman. The pharmacological basis of 
therapeutics, 13th edition,1996;848-856 
2. Amol Singam*, Ashok Chaudhari, Manda Nagrale;  Buprenorphine as an 
adjuvant in supraclavicular brachial plexus block, IJBAR (2012) 03(07). 
3. Bazin JE, Massoni C, Bruelle P,Fenies V,Groslier D, Schoeffler 
P.The addition of opioids to the local anaesthetics in brachial plexus 
block: The comparative effects of morphine, buprenorphine and 
sufentanil. Anaesthesia 1997;858-862 
4.  Bharat Paliwall,  Rakesh Karnawat.  Comparative study of effects of  
buprenorphine or clonidine as adjuvants to local anesthetics bupivacaine 
(0.25%) for supraclavicular brachial plexus block.  IOSR Journal of Dental 
and Medical Sciences IOSR-JDMS Volume 4, Issue 3 (Jan.- Feb. 2013), PP 
30-39. 
5. Brown DL. Brachial plexus anaesthesia: An analysis.Yale J Biol Med 
1993; 415-431 
6. Candido KD, Franco CD, Khan MA, Winnie AP, Raja DS: Buprenorphine 
added to the local anaesthetic for brachial plexus block to provide 
post operative analgesia in out patients. Regional anaesthesia and 
pain medicine 2002; 352-356 
7. Candido KD, Hennes J, Gonzalez S, Mikat-Stevens M, Pinzur M, 
Vasic V, Knezevic NN.Buprenorphine enhances and prolongs the 
postoperative analgesic effect of bupivacaine in patients receiving 
  
infragluteal sciatic nerve block. Anesthesiology; 113(6):1419-26; 
2010 
8. Daniel  Kapitzke,   Irina Vetter  and  Peter J Cabot . Endogenous 
opioid analgesia in peripheral tissues and the clinical implications for 
pain control ; 2005 Dec; 1(4): 279–297. 
9.  Fields H. L., Emson P., Leigh B., Gilbert R., Iversen L. L. Multiple opiate 
receptor sites on primary afferent fibres.1980; 351-353 
10.  Greher M, Schabert G, Kamholz LP. Ultrasound-guided  nerve block: a 
sono-anatomical study of a new methodological   approach. Anesthesiology 
2004. 
11. Guyton and Hall.Textbook of medical physiology,11th edition; 2006 ; 
598-609  
12. Harold Ellis, Stanley Feldman. Anatomy for Anaesthetists,8th edition; 
1997;   160-195  
13. Hassan AH, Ableitner A, Stein C. Inflammation of the rat paw enhances 
axonal transport of opioid receptors in the sciatic nerve and increases their 
density in the inflamed tissue. Neuroscience.1993;55:185–95 
14. John E. Tetzlaff. Peripheral nerve blocks – Morgan clinical 
anaesthesiology 1997,5th edition; 286-289 
15. Karakaya D.,  Büyükgöz F.,  Bariş S,  Güldoğuş, and  Tür A. 
“Addition of fentanyl to bupivacaine prolongs anesthesia and 
analgesia in axillary brachial plexus block,” Regional Anesthesia and 
Pain Medicine,2001; vol. 26, no. 5, pp. 434–438. 
  
16. Krutika B Rupera1, Birva N Khara1, Veena R Shah2, Bina K Parikh. 
Supraclavicular  brachial plexus block: Ultrasonography guided technique 
offer advantage over peripheral nerve stimulator guided technique. Volume 
3│Issue 3│July – Sept 2013 
17. Marhofer P,  Greher M  and   Kapral S. Ultrasound  guidance  in  regional  
anaesthesia.  British  Journal  of  Anaesthesia  2005 94 (1): 7–17. 
18. .Murphy DB, McCartney CJL, Chan VWS. Novel analgesic adjuncts for 
brachial plexus block: A systematic review. Anesth Analg ; 2000;90:1122–8. 
19.  Peterson MK. Ultrasound-guided nerve blocks. Br J Anaesth 2002; 88: 621–
624. 
20. Pinnock C.A.Peripheral nerve blocks,1996; 106-111 
21. Ritesh Dixit, Vivek Chakole, Gayatri.V. Tadwalkar   Effect of 
buprenorphine on post operative analgesia in supraclavicular brachial plexus 
block  using peripheral nerve locator. Journal of Evolution of Medical and 
dental Sciences/ Volume 2/ Issue 2/ January 14, 2013. 
22. Robert K. Stoelting.M,4th edition;2006; 179-208 
23. Robert K. Stoelting.M,4th edition;2006; 87- 120 
24. Ronald D.Miller. Miller’s Anaesthesia,7th edition; 2009 ; 2007 -2045 
25. Stein C, Schafer M, Cabot PJ. Peripheral opioid analgesia. Pain 
Reviews. 1997;4:173–87. 
26. Vermeylen K ,  Engelen S ,  Sermeus L,  Soetens F  and  Van de Velde M. 
 Supraclavicular brachial plexus blocks : Review and current practice. Acta 
Anaesth. Belg., 2011, 62, 15-21 
  
27. Viel EJ, Eledjam JJ, De La Coussaye JE,D'Athis F. Brachial plexus block 
with opioids for postoperative pain relief: comparison between 
buprenorphine and morphine. Reg Anesth. Nov-Dec; 14(6):274-8; 1989 
28. William F.Ganong. Review of medical physiology 2001,24th edition; 49-60 
29. Williams SR, Chouinard P, Arcand G. Ultrasound guidance speeds        
 execution and improves the quality of supraclavicular block. Anaesth Analg  
2003; 97:1518-23 
30.  Winnie A.P.,Ramamoorthy S, Tay C.H.. Patel K.P. and Durrani Z. 
Pharmacokinetics of local anaesthetics during brachial plexus 
blocks.Anaesthesia and analgesia 1997; 852-861 
31.  Wylie and Churchill Davidson. The practice of Anaesthesia. The 
pharmacology of local anaesthetics. 1985,5th edition; 830-850 
 
 
  
  
PROFORMA 
NAME:  AGE/SEX: 
IP.NO:  WEIGHT:                          
DIAGNOSIS SURGICAL PROCEDURE DONE: 
PRE OP ASSESSMENT: 
HISTORY 
EXAMINATION: 
AIRWAY: 
ASA status:  
PREOP PR:        PREOP BP:   
MEASURES OF STUDY OUTCOME: 
ONSET OF SENSORY BLOCKADE:                                                                                                                        
Time in 
mins 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Loss of 
pinprick 
sensation 
               
ONSET OF MOTOR BLOCKADE: 
Time in 
mins 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Loss of 
shoulder 
abduction 
               
  
  
HEMODYNAMIC PARAMETERS: 
Time in 
mins 
0 1 5 10 15 30 60 90 120 240 
Heart rate           
Systolic 
BP 
          
Diastolic 
BP 
          
Mean BP           
Respiratory 
rate 
          
Spo2           
DURATION OF SURGERY (IN MINS) : 
POST OPERATIVE PARAMETERS:  
Time in 
hours 
0 1 2 3 4 5 6 8 10 12 16 20 24 
Visual 
analogue 
score 
             
Ramsay 
sedation 
score 
             
Side 
effects 
             
DUARATION OF ANALGESIA: 
POST OP ANALGESIC INITIATION  TIME: 
  
INFORMATION TO PARTICIPANTS 
Investigator                     : Dr.G.ARCHANA 
Name of the Participant: 
Title  “A Prospective, randomized study comparing ultrasound 
guided  supraclavicular brachial plexus  block  using bupivacaine with 
bupivacaine and buprenorphine in  patients undergoing elective upper 
limb orthopaedic surgeries” 
You are invited to take part in this research study. We have got approval from the 
IEC. Your are asked to participate because you satisfy the eligibility criteria .We want to 
compare and study the analgesic efficacy of bupivaccaine with bupivaccaine and 
buprenorphine  in supraclavicular brachial plexus block. 
What is the Purpose of the Research: 
For upper limb orthopaedic surgeries, patient is given ultrasound guided  
supraclavicular brachial plexus block either using bupivaccaine or bupivaccaine and 
buprenorphine. This study is done to compare the supraclavicular block using bupivaccaine 
with bupivaccaine and buprenorphine with respect to,  
1. Intraoperative hemodynamics 
 
2. Post operative analgesia using visual analogue scale pain score. 
 
3. Post op analgesic initiation time 
 
The Study Design:     60 patients presenting for elective upper limb orthopaedic  
surgeries were randomly assigned to two groups .  
Group1-  preoperative  supraclavicular block using bupivaccaine . 
 
Group 2- preoperative supraclavicular block using bupivaccaine and buprenorphine. 
  
Benefits: Pre operative supraclavicular block , maintains intra operative 
hemodynamics, causes excellent & prolonged post operative pain releif.  
Problems associated with supraclavicular blocks are avoided.                     
Discomforts and risks :  
May cause nausea, vomiting, constipation- prevention given with appropriate drugs.                 
 May cause respiratory depression –patients with pulmonary fibrosis, COPD  are 
excluded from study. 
May cause pneumothorax-  this will be prevented by using ultrasound guided 
technique. 
This intervention has been shown to be well tolerated as shown by previous studies. 
And if you do not want to participate you will have alternative of setting the standard 
treatment and your safety is our prime concern. 
Confidentiality of data and details of study and patients details concerned with this 
research will be strictly maintained. 
All tests , medicine,and medical services concerned with this  research will be 
provided free of cost to the patient. 
Time : 
Date : 
Place :                                                                                                       
Signature / Thumb Impression of Patient 
Patient Name: 
Signature of the Investigator : ____________________________ 
Name of the Investigator : ___________________________ 
  
PATIENT CONSENT FORM 
Study title “A Prospective, randomized study comparing ultrasound 
guided  supraclavicular brachial plexus block  using bupivacaine with 
bupivacaine and buprenorphine in  patients undergoing elective upper 
limb orthopaedic surgeries” 
     Study center: INSTITUTE OF ANAESTHESIOLOGY AND 
CRITICAL CARE, MADRAS MEDICAL COLLEGE & GOVT GENERAL 
HOSPITAL, CHENNAI 600003. 
         
 
 
Participant name :    Age:  Sex:                                
I.P.No: 
I confirm that I have understood the purpose of procedure for the 
above study . I have the opportunity to ask the question and all my questions 
and doubts have been answered to my satisfaction. 
I have been explained about the pitfall in the procedure.  I have been 
explained about the safety,advantage and disadvantage of the technique. 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at anytime without giving any reason. 
I understand that investigator ,regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to current study and any further research that may be conducted in 
  
relation to it, even if I withdraw from the study . I understand that my identity 
will not be revealed in any information released to third parties or published , 
unless as required under the law . I agree not to restrict the use of any data or 
results that arise from the study . 
 
Time:          
Date:                                                                                             Signature / 
thumb impression of patient  
Place:                                                                                            Patient 
name: 
Signature of the investigator: 
Name of the investigator: 
  
  
 
 
  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
 
 
 
 
 
 
